Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lenvatinib and everolimus work in treating patients with
carcinoid tumors that have spread to other places in the body (advanced) and cannot be
removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth.